Company Description
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.
Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases.
In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis.
Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases.
The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019.
Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
| Country | Canada |
| Founded | 2018 |
| IPO Date | Feb 8, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 96 |
| CEO | Dr. Peter Maag Ph.D. |
Contact Details
Address: 5980 Horton Street, Suite 550 Emeryville, California 94608 United States | |
| Phone | 5106268331 |
| Website | kyvernatx.com |
Stock Details
| Ticker Symbol | KYTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $22.00 |
| CIK Code | 0001994702 |
| Employer ID | 83-1365441 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter Maag Ph.D. | Chief Executive Officer and Director |
| Karen Walker | Chief Technology Officer |
| Dr. James Chung M.D., Ph.D. | Chief Medical Officer |
| Ryan Jones | Chief Financial Officer |
| Dr. Tom Van Blarcom Ph.D. | Senior Vice President and Head of Research |
| Portia Serame | Vice President of Human Resources |
| Dr. Dominic Borie M.D., Ph.D. | President of Research and Development |
| Devin Murray | Senior Vice President of Partnerships and Alliances |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 3, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | 8-K | Current Report |
| Feb 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | 8-K | Current Report |
| Feb 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 8, 2024 | 424B4 | Prospectus |
| Feb 8, 2024 | CERT | Certification by an exchange approving securities for listing |